Liver Ultrasound Attenuation: An Ultrasound Attenuation Index for Liver Steatosis Assessment.
Journal
Ultrasound quarterly
ISSN: 1536-0253
Titre abrégé: Ultrasound Q
Pays: United States
ID NLM: 8809459
Informations de publication
Date de publication:
01 Jun 2022
01 Jun 2022
Historique:
pubmed:
31
3
2022
medline:
11
6
2022
entrez:
30
3
2022
Statut:
epublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) is the most widespread chronic liver disease type in the Western countries. Ultrasound (US) is used for NAFLD and hepatic steatosis (HS) grading. The most popular US method for NAFLD assessment is the hepatorenal index (HRI), but because of its limitations, other noninvasive methods have been developed. The Resona 7 US system has recently incorporated an US attenuation-related quantitative feature, liver ultrasound attenuation (LiSA), for HS estimation. The purpose of this study is to compare LiSA's and HRI's performance on NAFLD assessment. A total of 159 NAFLD patients having a magnetic resonance imaging-proton density fat fraction (MRI-PDFF) examination were examined by 2 radiologists, who performed LiSA and HRI measurements in the liver. Correlation of LiSA's and HRI's measurements with MRI-PDFF values was calculated through Pearson correlation coefficient (PCC). To further investigate the performance of LiSA and HRI, optimum cutoffs, provided by the literature, were used to correspond HS grades to MRI-PDFF results. Moreover, a receiver operating characteristic (ROC) analysis on LiSA measurements and steatosis grades was performed. Magnetic resonance imaging-PDFF was better correlated with LiSA (PCC = 0.80) than HRI (PCC = 0.67). Receiver operating characteristic analysis showed better performance range for LiSA (77.8%-91.8%) than for HRI (72.8%-85.4%) on all HS grades for all studies used for corresponding MRI-PDFF values to HS grades. The results indicate that LiSA is more accurate than HRI in HS differentiation and can lead to more accurate grading of HS on NAFLD patients.
Identifiants
pubmed: 35353797
doi: 10.1097/RUQ.0000000000000605
pii: 00013644-202206000-00005
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
124-132Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
P.S.Z. has, during the last years, participated in webinars and live courses in cooperation with Mindray, for which he received honoraria. Diagnostic Echotomography has undertaken a clinical feedback project on behalf of the US equipment manufacturer company, Mindray. The project involved the loan of a Resona7 US system, from the Mindray part, and the sharing of clinical feedback, from the Diagnostic Echotomography part. For the remaining authors, no conflict of interest is declared.
Références
Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol . 2011;9:524–530.e1; quiz e60. doi:10.1016/j.cgh.2011.03.020.
doi: 10.1016/j.cgh.2011.03.020
Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol . 2005;42:132–138. doi:10.1016/j.jhep.2004.09.012.
doi: 10.1016/j.jhep.2004.09.012
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology . 2006;43:S99–S112. doi:10.1002/hep.20973.
doi: 10.1002/hep.20973
Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology . 2010;51:1820–1832. doi:10.1002/hep.23594.
doi: 10.1002/hep.23594
Younossi ZM. Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol . 2019;70:531–544. doi:10.1016/J.JHEP.2018.10.033.
doi: 10.1016/J.JHEP.2018.10.033
Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol . 2007;47:598–607. doi:10.1016/j.jhep.2007.07.006.
doi: 10.1016/j.jhep.2007.07.006
Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab . 2005;90:1578–1582. doi:10.1210/jc.2004-1024.
doi: 10.1210/jc.2004-1024
Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol . 2003;15:539–543. doi:10.1097/01.meg.0000059112.41030.2e.
doi: 10.1097/01.meg.0000059112.41030.2e
Neuberger J, Patel J, Caldwell H, et al. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of pathology. Gut . 2020;69:1382–1403. doi:10.1136/gutjnl-2020-321299.
doi: 10.1136/gutjnl-2020-321299
Thomaides-Brears HB, Alkhouri N, Allende D, et al. Incidence of complications from percutaneous biopsy in chronic liver disease: a systematic review and meta-analysis [published online June 15, 2021]. Dig Dis Sci . doi:10.1007/s10620-021-07089-w.
doi: 10.1007/s10620-021-07089-w
Carey E, Carey WD. Noninvasive tests for liver disease, fibrosis, and cirrhosis: is liver biopsy obsolete? Cleve Clin J Med . 2010;77:519–527. doi:10.3949/ccjm.77a.09138.
doi: 10.3949/ccjm.77a.09138
Vuppalanchi R, Unalp A, Van Natta ML, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol . 2009;7:481–486. doi:10.1016/j.cgh.2008.12.015.
doi: 10.1016/j.cgh.2008.12.015
Ratziu V, Charlotte F, Heurtier A, et al; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology . 2005;128:1898–1906. doi:10.1053/j.gastro.2005.03.084.
doi: 10.1053/j.gastro.2005.03.084
Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology . 2002;123:745–750. doi:10.1053/gast.2002.35354.
doi: 10.1053/gast.2002.35354
Kodama Y, Ng CS, Wu TT, et al. Comparison of CT methods for determining the fat content of the liver. Am J Roentgenol . 2007;188:1307–1312. doi:10.2214/AJR.06.0992.
doi: 10.2214/AJR.06.0992
Chung JH, Ahn HS, Kim SG, et al. The usefulness of transient elastography, acoustic-radiation-force impulse elastography, and real-time elastography for the evaluation of liver fibrosis. Clin Mol Hepatol . 2013;19:156–164. doi:10.3350/cmh.2013.19.2.156.
doi: 10.3350/cmh.2013.19.2.156
Limanond P, Raman SS, Lassman C, et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology . 2004;230:276–280. doi:10.1148/radiol.2301021176.
doi: 10.1148/radiol.2301021176
Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol . 2009;51:433–445. doi:10.1016/j.jhep.2009.05.023.
doi: 10.1016/j.jhep.2009.05.023
Guiu B, Loffroy R, Hillon P, et al. Magnetic resonance imaging and spectroscopy for quantification of hepatic steatosis: urgent need for standardization! J Hepatol . 2009;51:1082–1083. doi:10.1016/j.jhep.2009.09.006.
doi: 10.1016/j.jhep.2009.09.006
Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis . 2007;11:37–54, viii. doi:10.1016/j.cld.2007.02.014.
doi: 10.1016/j.cld.2007.02.014
Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol . 2007;102:2716–2717. doi:10.1111/j.1572-0241.2007.01520.x.
doi: 10.1111/j.1572-0241.2007.01520.x
Lupşor-Platon M, Stefănescu H, Mureşan D, et al. Noninvasive assessment of liver steatosis using ultrasound methods. Med Ultrason . 2014;16:236–245. doi:10.11152/mu.2013.2066.163.1mlp.
doi: 10.11152/mu.2013.2066.163.1mlp
Chen CL, Cheng YF, Yu CY, et al. Living donor liver transplantation: the Asian perspective. Transplantation . 2014;97(suppl 8):S3.
Mathiesen UL, Franzén LE, Aselius H, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis . 2002;34:516–522.
Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology . 2011;54:1082–1090. doi:10.1002/hep.24452.
doi: 10.1002/hep.24452
Strauss S, Gavish E, Gottlieb P, et al. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol . 2007;189:W320–W323. doi:10.2214/AJR.07.2123.
doi: 10.2214/AJR.07.2123
Taylor KJ, Gorelick FS, Rosenfield AT, et al. Ultrasonography of alcoholic liver disease with histological correlation. Radiology . 1981;141:157–161. doi:10.1148/radiology.141.1.6270725.
doi: 10.1148/radiology.141.1.6270725
Meek DR, Mills PR, Gray HW, et al. A comparison of computed tomography, ultrasound and scintigraphy in the diagnosis of alcoholic liver disease. Br J Radiol . 1984;57:23–27.
Marshall RH, Eissa M, Bluth EI, et al. Hepatorenal index as an accurate, simple, and effective tool in screening for steatosis. AJR Am J Roentgenol . 2012;199:997–1002. doi:. doi: 10.2214/AJR.11.6677.
doi: . doi: 10.2214/AJR.11.6677
Borges VF, Diniz AL, Cotrim HP, et al. Sonographic hepatorenal ratio: a noninvasive method to diagnose nonalcoholic steatosis. J Clin Ultrasound . 2013;41:18–25. doi:10.1002/jcu.21994.
doi: 10.1002/jcu.21994
Webb M, Yeshua H, Zelber-Sagi S, et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol . 2009;192:909–914. doi:10.2214/AJR.07.4016.
doi: 10.2214/AJR.07.4016
Dioguardi Burgio M, Imbault M, Ronot M, et al. Ultrasonic adaptive sound speed estimation for the diagnosis and quantification of hepatic steatosis: a pilot study. Ultraschall Med . 2019;40:722–733. doi:10.1055/A-0660-9465.
doi: 10.1055/A-0660-9465
Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol . 2010;36:1825–1835. doi:10.1016/j.ultrasmedbio.2010.07.005.
doi: 10.1016/j.ultrasmedbio.2010.07.005
Sasso M, Miette V, Sandrin L, et al. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol . 2012;36:13–20. doi:10.1016/j.clinre.2011.08.001.
doi: 10.1016/j.clinre.2011.08.001
Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. J Viral Hepat . 2012;19:244–253. doi:10.1111/j.1365-2893.2011.01534.x.
doi: 10.1111/j.1365-2893.2011.01534.x
Shi KQ, Tang JZ, Zhu XL, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol . 2014;29:1149–1158. doi:10.1111/jgh.12519.
doi: 10.1111/jgh.12519
Caussy C, Alquiraish MH, Nguyen P, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology . 2018;67:1348–1359. doi:10.1002/hep.29639.
doi: 10.1002/hep.29639
Myers RP, Pollett A, Kirsch R, et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int . 2012;32:902–910. doi:10.1111/j.1478-3231.2012.02781.x.
doi: 10.1111/j.1478-3231.2012.02781.x
de Lédinghen V, Vergniol J, Foucher J, et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int . 2012;32:911–918. doi:10.1111/j.1478-3231.2012.02820.x.
doi: 10.1111/j.1478-3231.2012.02820.x
Ferraioli G, Maiocchi L, Raciti MV, et al. Detection of liver steatosis with a novel ultrasound-based technique: a pilot study using MRI-derived proton density fat fraction as the gold standard. Clin Transl Gastroenterol . 2019;10:e00081. doi:10.14309/CTG.0000000000000081.
doi: 10.14309/CTG.0000000000000081
Fujiwara Y, Kuroda H, Abe T, et al. The B-mode image-guided ultrasound attenuation parameter accurately detects hepatic steatosis in chronic liver disease. Ultrasound Med Biol . 2018;44:2223–2232. doi:10.1016/J.ULTRASMEDBIO.2018.06.017.
doi: 10.1016/J.ULTRASMEDBIO.2018.06.017
Tada T, Kumada T, Toyoda H, et al. Utility of attenuation coefficient measurement using an ultrasound-guided attenuation parameter for evaluation of hepatic steatosis: comparison with MRI-determined proton density fat fraction. AJR Am J Roentgenol . 2019;212:332–341. doi:10.2214/AJR.18.20123.
doi: 10.2214/AJR.18.20123
Tamaki N, Koizumi Y, Hirooka M, et al. Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. Hepatol Res . 2018;48:821–828. doi:10.1111/HEPR.13179.
doi: 10.1111/HEPR.13179
Zeng Q, Song Z, Zhao Y, et al. Controlled attenuation parameter by vibration-controlled transient elastography for steatosis assessment in members of the public undergoing regular health checkups with reference to magnetic resonance imaging-based proton density fat fraction. Hepatol Res . 2020;50:578–587. doi:10.1111/hepr.13481.
doi: 10.1111/hepr.13481
Tang A, Desai A, Hamilton G, et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology . 2015;274:416–425. doi:10.1148/radiol.14140754.
doi: 10.1148/radiol.14140754
Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology . 2016;150:626–637.e7. doi:10.1053/j.gastro.2015.11.048.
doi: 10.1053/j.gastro.2015.11.048
Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology . 2017;152:598–607.e2. doi:10.1053/j.gastro.2016.10.026.
doi: 10.1053/j.gastro.2016.10.026
Bartlett JW, Frost C. Reliability, repeatability and reproducibility: analysis of measurement errors in continuous variables. Ultrasound Obstet Gynecol . 2008;31:466–475. doi:10.1002/uog.5256.
doi: 10.1002/uog.5256
McGraw K, Wong S. Forming inferences about some intraclass correlation coefficients. Psychol Methods . 1996;9:3582–3598.
Pu K, Wang Y, Bai S, et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol . 2019;19:51. doi:10.1186/s12876-019-0961-9.
doi: 10.1186/s12876-019-0961-9
Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol . 2017;66:1022–1030. doi:10.1016/j.jhep.2016.12.022.
doi: 10.1016/j.jhep.2016.12.022
Gatos I, Drazinos P, Yarmenitis S, et al. Comparison of sound touch elastography, shear wave elastography and vibration-controlled transient elastography in chronic liver disease assessment using liver biopsy as the “reference standard”. Ultrasound Med Biol . 2020;46:959–971. doi:10.1016/j.ultrasmedbio.2019.12.016.
doi: 10.1016/j.ultrasmedbio.2019.12.016
Hu YY, Dong NL, Qu Q, et al. The correlation between controlled attenuation parameter and metabolic syndrome and its components in middle-aged and elderly nonalcoholic fatty liver disease patients. Medicine (Baltimore) . 2018;97:e12931. doi:10.1097/MD.0000000000012931.
doi: 10.1097/MD.0000000000012931
de Lédinghen V, Vergniol J, Capdepont M, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol . 2014;60:1026–1031. doi:10.1016/J.JHEP.2013.12.018.
doi: 10.1016/J.JHEP.2013.12.018
Sporea I, Bota S, Gradinaru-Taşcău O, et al. Which are the cut-off values of 2D-shear wave elastography (2D-SWE) liver stiffness measurements predicting different stages of liver fibrosis, considering transient elastography (TE) as the reference method? Eur J Radiol . 2014;83:e118–e122. doi:10.1016/j.ejrad.2013.12.011.
doi: 10.1016/j.ejrad.2013.12.011